Pictet Asset Management Holding SA grew its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 10,434.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 661,586 shares of the company’s stock after purchasing an additional 655,306 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Edgewise Therapeutics were worth $26,860,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently bought and sold shares of EWTX. Parallel Advisors LLC boosted its holdings in shares of Edgewise Therapeutics by 64.9% during the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock worth $33,000 after acquiring an additional 406 shares during the period. KBC Group NV acquired a new position in shares of Edgewise Therapeutics in the first quarter valued at approximately $49,000. Sterling Capital Management LLC increased its stake in shares of Edgewise Therapeutics by 840.2% during the third quarter. Sterling Capital Management LLC now owns 2,360 shares of the company’s stock worth $96,000 after purchasing an additional 2,109 shares during the period. GAMMA Investing LLC increased its stake in shares of Edgewise Therapeutics by 26.5% during the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company’s stock worth $108,000 after purchasing an additional 559 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Edgewise Therapeutics during the third quarter worth approximately $225,000.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the company. William Blair began coverage on Edgewise Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. The Goldman Sachs Group boosted their price target on Edgewise Therapeutics from $32.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Edgewise Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Thursday, October 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Edgewise Therapeutics in a research report on Wednesday, October 14th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $52.83.
Insider Buying and Selling at Edgewise Therapeutics
In other news, CFO Michael Nofi sold 4,442 shares of Edgewise Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $45.43, for a total value of $201,800.06. Following the completion of the sale, the chief financial officer directly owned 6,495 shares in the company, valued at approximately $295,067.85. The trade was a 40.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 21.30% of the company’s stock.
Edgewise Therapeutics Stock Up 2.2%
Shares of Edgewise Therapeutics stock opened at $47.57 on Thursday. Edgewise Therapeutics, Inc. has a twelve month low of $19.76 and a twelve month high of $48.78. The company has a 50-day simple moving average of $41.18 and a two-hundred day simple moving average of $36.81. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of 5.81 and a beta of 0.39.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $10.18. On average, sell-side analysts anticipate that Edgewise Therapeutics, Inc. will post 6.92 earnings per share for the current fiscal year.
Edgewise Therapeutics Profile
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.
Further Reading
- Five stocks we like better than Edgewise Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding EWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report).
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
